Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.86 +2.42 (+2.48%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
2 Dividend Stocks to Buy and Never Sell
These two are rock-solid businesses with strong dividend programs. 
Via The Motley Fool
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
From Daiichi Sankyo
Via Business Wire
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Goldman Sachs discusses Gardasil's performance in China with Merck's Joe Romanelli. Gardasil faces challenges due to market issues and partner Zhifei's operational problems, impacting Q2 sales. Despite... 
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
Merck Analysts Slash Their Forecasts After Q2 Results
Via Benzinga
Analyzing Merck &amp; Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Is It Time to Buy July's Worst-Performing Dow Jones Stocks?
Most Dow stocks were winners last month, but not these. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atlassian, MicroStrategy, New Oriental, and Western Digital. 
Via Benzinga
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost. 
Via The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark reposed its faith in the company. 
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies. 
Via The Motley Fool
Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone
Market sentiment declines as Fear & Greed index moves to 'Fear' zone. Dow Jones gains ahead of major earnings and Fed policy decision. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck (MRK) Q2 2024 Earnings Call Transcript
MRK earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.